| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 3.215 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 4.790 | 1.190 | 820 | 424 | 0 | 336 | 124 | 4 | 43 | 0 |
| Total Expenses - EUR | 6.768 | 1.604 | 1.716 | 4.227 | 25 | 1.333 | 498 | 1 | 172 | 0 |
| Gross Profit/Loss - EUR | -1.978 | -414 | -896 | -3.803 | -25 | -998 | -374 | 3 | -129 | 0 |
| Net Profit/Loss - EUR | -2.083 | -414 | -896 | -3.803 | -25 | -998 | -374 | 3 | -129 | 0 |
| Employees | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Melbimed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 16.882 | 16.230 | 15.873 | 12.021 | 11.775 | 11.884 | 11.745 | 11.780 | 11.788 | 11.722 |
| Inventories | 4.417 | 4.372 | 4.298 | 710 | 696 | 683 | 668 | 670 | 668 | 664 |
| Receivables | 11.331 | 11.264 | 11.300 | 11.123 | 10.910 | 11.036 | 10.915 | 10.948 | 10.958 | 10.897 |
| Cash | 1.133 | 594 | 275 | 188 | 169 | 165 | 162 | 162 | 162 | 161 |
| Shareholders Funds | -19.142 | -19.362 | -19.930 | -23.367 | -22.940 | -23.503 | -23.355 | -23.424 | -23.482 | -23.351 |
| Social Capital | 225 | 223 | 219 | 215 | 211 | 207 | 202 | 203 | 202 | 201 |
| Debts | 36.024 | 35.591 | 35.802 | 35.388 | 34.715 | 35.387 | 35.100 | 35.205 | 35.270 | 35.073 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Melbimed S.r.l.